Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Status Completed

Clinical Trial Summary

The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.

Clinical Trial Description

This is a single-center, open-label, non-randomized, prospective phase II trial. Sutent treatment will be continued until disease progression, or excessive toxicity (as determined by treating physician or primary investigator), or until a maximum of eight cycles, whichever duration is shorter. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00434109
Study type	Interventional
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact
Status	Completed
Phase	Phase 2
Start date	November 2006
Completion date	February 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04837885` - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases	Phase 2
Completed	`NCT00789841` - Gastrointestinal Motility in Patients With Neuroendocrine Tumors	N/A
Recruiting	`NCT05069220` - 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor	Early Phase 1
Completed	`NCT05816720` - Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Active, not recruiting	`NCT04400474` - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Completed	`NCT01849523` - Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study	N/A
Recruiting	`NCT01448083` - Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours	N/A
Completed	`NCT00804336` - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors	Phase 1
Active, not recruiting	`NCT02092714` - Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Terminated	`NCT04073017` - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency	N/A
Completed	`NCT02472678` - Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor	N/A
Completed	`NCT02481804` - Optimal Feeding for NET Patients	N/A
Completed	`NCT02147106` - Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
Completed	`NCT00165230` - Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT03012789` - Surgical Intervention and the NETest	N/A
Not yet recruiting	`NCT02038738` - 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors	Phase 1/Phase 2
Completed	`NCT01024387` - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Phase 2
Terminated	`NCT00227617` - Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors	Phase 2/Phase 3
Terminated	`NCT02177773` - GA-68 DOTA-TOC of Somatostatin Positive Malignancies	Phase 1/Phase 2